Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hope springs eternal

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on May 13, 2021 6:13am

139 Views

Post# 33189722

RE:RE:Hope springs eternal

Pandora wrote:

markymark11 wrote: I'm reading about another biotech -- their lead drug candidate was only in phase 1a (with phase 2 scheduled to begin mid- to late-2021) when they received a buy out deal for $1.9 billion USD.

GLTA!

For me those are the ones that someone else always owns - not me. I own the ones like ATE at the end of Phase 2 -- where I was buying while unbeknownst to me Dan & John were selling a boatload on the same day.